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ABSTRACT 
The spread of multidrug-resistant strains of bacteria makes it necessary to discover new classes of antibacterial and 
compounds that inhibit these resistant mechanisms. Hence, this study investigated the antimicrobial activities of Gano-
derma lucidum and Deadaleopsis confragosa extracts against some bacterial isolates of medical importance. Using agar 
well diffusion assay, aqueous, ethanolic and petroleum ether extracts were obtained from Ganoderma lucidum and 
Daedaleopsis confragosa and assayed for antimicrobial on five bacterial species, viz: Pseudomonas aeruginosa, Es-
cherichia coli, Staphylococcus aureus, Proteus mirabilis and Klebsiella pneumoniae. In vitro bioassay revealed that the 
aqueous extract of G. lucidum inhibited P. aeruginosa S. aureus, E. coli and K. Pneumoniae with inhibition zones of 
11.0 ± 0.02 mm, 10.0 ± 0.02 mm, 13.0 ± 0.03 mm and 14.0 ± 0.0 mm respectively. The ethanolic extract of G. lucidum 
also inhibited P. aeruginosa, S. aureus and E. coli with inhibition zones 12.0 ± 0.01 mm, 11.0 ± 0.02 mm and 16.0 ± 
0.01 mm. Petroleum ether extract of G. lucidum inhibited P. aeruginosa, S. aureus and E. coli with inhibition zones of 
12.0 ± 0.01 mm, 11.0 ± 0.03 mm and 12.0 ± 0.02 mm. For Daedaleopsis confragosa, the aqeous extract inhibited P. 
aeruginosa and E. coli with inhibition zones of 12.0 ± 0.01 and 12.0 ± 0.02 mm respectively while the petroleum ether 
extract inhibited S. aureus and E. coli with inhibition zones of 19.0 ± 0.02 mm and 13.0 ± 0.01 mm respectively. All 
these inhibitions on clinical isolates are therefore attributed to the presence of some bioactive compound as shown by 
the phytochemical screening of the mushrooms which include tannins, phenolics, flavonoids and saponin. 
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1. Introduction 
Mushroom describes a variety of gilled fungi, with or 
without stems and the term is used more generally to 
describe fleshing fruiting bodies of some basidiomycota 
[1]. Medicinal mushrooms are mushrooms used in the 
practice of medicine and many species of mushrooms 
have been used in folk medicines for thousands of years. 
[2] has also reported the importance of mushrooms as 
sources of food nutrients as well as for medicinal pur- 
poses in the orients. [3] also reported that some mush- 
rooms inhibit tumor growth and enhance aspect of the 
immune system and thus, have been subjects of research 
for approximately 50 years. However, studied mushroom 
extracts have consistently shown to be safe and well tol- 
erated, also, the medicinal value of these mushrooms lied 
in some chemical substances that produce a definite 
physiological action on human body [3]. It is recognized 
in some developing countries that mushrooms are the 
main medicinal source to treat infectious diseases. In 
these countries living conditions are crowded by poor 
hygiene, diarrhea and dysentery and some other deadly 
diseases caused by bacteria, fungi and other microorgan- 
isms resulting to high morbidity and mortality. 
Research conducted with mushroom has led to the dis- 
covery of drugs such as penicillin, endosporin, griseo- 
fulvin, cephalosporin and so on. Examples of mushroom 
species with medicinal potentials of importance include 
Reishi (Ganoderma lucidum), shiitake (Lentinula edodes), 
Grifola fondosa, G. unbellaus and so on. Reishi is also 
known to contain various chemical substances, including 
more than 119 different types of triterpenes and several 
types of polysaccharides [4]. Presence of immune poly- *Corresponding author. 
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sacchardes also known as beta-glucan makes these me- 
dicinal mushrooms of high medicinal value [5]. 
Mushrooms are also known to contain antioxidants 
such as tocopherols, phenolic compounds and carote- 
noids. Research has shown that some medicinal mush- 
rooms may be able to lower elevated blood sugar levels. 
Mushrooms noted for this ability include Reishi, Agari- 
cus campestris, A. blazei, Agrocybe aegerita, and Cor- 
dyceps [6]. Explanation for this effect is limited, with the 
exception of the maitake mushroom which has ability to 
lower blood sugar levels [7]. It has been explained by the 
fact that the mushroom naturally contains a compound 
known as an alpha-glycosidase inhibitor [8]. 
Antimicrobial agents vary in their selective toxicity. 
Some act in a non-selective manner and have similar 
effect on all types of cells. Antimicrobial agents with se- 
lective toxicity are especially useful as chemotherapeu- 
tic agents in such treating infectious diseases and may be 
a function of specific receptor requirement for drug at- 
tachment [9]. Therefore, the aim of this work is to deter- 
mine the antimicrobial activities and bioactive ingredi- 
ents of Ganoderma lucidum and Daedaleopsis confra- 
gosa and compare the efficacy of the mushroom extracts 
with some standard antibiotics. 
2. Materials and Methods 
2.1. Collection of Mushroom Samples 
Mushroom samples used for this research work were 
obtained on the 16th April, 2010 from a cocoa farm very 
close to Joseph Ayo Babalola University, Ikeji-Arakeji, 
Osun State, Nigeria. They were identified in the Depart- 
ment of Biological Science, Joseph Ayo Babalola Uni- 
versity and authenticated at the Department of Microbi- 
ology, Federal University of Technology, Akure. The mush- 
rooms were washed with distilled water and sundried for 
four days. It was later oven dried for 24 hr at 45˚C. The 
dried samples were pulverized using industrial blender 
(exceler). 
2.2. Collection of Isolates 
Clinical isolates of Staphylococcus aureus, Escherichia 
coli, Proteus vulgaris, Klebsiella pneumonia and Pseu- 
domonas aeruginosa were collected from Obafemi Awo- 
lowo University teaching hospital, Ile-Ife, Osun State, 
Nigeria. The isolates were resuscitated in nutrient agar 
and maintained at 4˚C for further use. 
2.3. Phytochemical Analysis 
The following bioactive compounds were assayed for: 
tannis, phenolics, saponins, flavoniods, steroid and phlo- 
batannins using the method described by Sofowora et al. 
[10]. 
2.4. Determination of the Antimicrobial Activity 
of the Mushroom Samples 
Antimicrobial potentials of extracts from G. lucidum, D. 
confragosa and some standard antibiotics were assayed 
for using the method of [11]. 
2.5. Statistical Analysis 
Quantitative data were expressed as mean  standard 
deviation. Statistical evaluation of the data was per- 
formed using one-way analysis of variance followed by 
Duncan’s multiple range test at 5% level of significance 
i.e. P ≤ 0.05 [12]. 
3. Results 
3.1. Bioactive Components of G. lucidum and 
D. confragosa 
Table 1 shows the phytochemical components present in 
the aqeous, ethanolic and petroleum ether extracts of G. 
lucidum and D. confragosa. 
3.2. Antimicrobial Activities of G. lucidum and 
D. confragosa 
Table 2 shows the antimicrobial activities of the mush- 
room samples. Highest zone of inhibition of 16.0 ± 0.01 
mm was observed against E. coli on ethanolic extract of 
G. lucidum while P. vulgaris and K. pneumonia were 
resistant. Petroleum ether extract of G. lucidum inhibited 
P. aeruginosa, S. aureus and E. coli with 12.0 ± 0.01 mm, 
11.0 ± 0.03 mm and 12.0 ± 0.02 mm respectively. How- 
ever, P. vulgaris, and K. pneumoniae were found to be 
resistant. Also, aqueous extract of G. lucidum against P. 
aeruginosa, S. aureus, E. coli and K. pneumoniae was 
pronounced with inhibitory zones of 11.0 ± 0.02 mm, 
10.0 ± 0.02 mm, 13.0 ± 0.03 mm and 14.0 ± 0.00 mm 
respectively while P. mirabilis was resistant. The ethano- 
lic extract of D. confragosa against P. aeruginosa, S. 
aureus, P. vulgaris, E. coli and K. pneumoniae were not 
noticeable while S. aureus and E. coli had 19.0 ± 0.02 
mm and 13.0 ± 0.01 mm for the petroleum ether extract 
of D. confragosa with P. aeruginosa, P. vulgaris and K. 
pneumoniae being resistant. For the antibacterial activi- 
ties of the aqueous extract of D. confragosa, S. aureus 
and E. coli had zones of inhibition of 12.0 ± 0.01 mm 
and 12.0 ± 0.01 mm respectively with P. aeruginosa, P. 
vulgaris and K. pneumoniae being resistant. The standard 
antibiotics assayed for showed the Amoxil against P. ae- 
ruginosa, S. aureus and E. coli with inhibition zones of 
11.0 ± 0.02 mm, 14.0 ± 0.01 mm and 8.0 ± 0.01 mm re- 
spectively, while Ampicillin inhibited S. aureus, P. vul- 
garis, E. coli and K. pneumoniae with inbihition zones of 
11.0 ± 0.02 mm, 14.0 ± 0.03 mm, 11.0 ± 0.02 mm and 
18.0 ± 0.01 mm respectively. Ampiclox also inhibited S. 
Copyright © 2013 SciRes.                                                                               OJMM 
S. FAKOYA  ET  AL. 
Copyright © 2013 SciRes.                                                                               OJMM 
137
 
Table 1. Phytochemical components of D. confragosa and G. lucidum. 
Mushroom samples Flavonoid Tannins Saponins Phenolics Phlabotanins Steroids 
Aeg - - - - - - 
Aed - + - - - - 
Eeg + + + - - - 
Eed - - - - - - 
Peg - + - + - + 
Ped - + - + - + 
Key: Aeg = aqueous extract of G. lucidum; Aed = aqueous extract D. confragosa; Eeg = ethanolic extract G. lucidum; Eed = ethanolic extract D. Confragosa; 
Peg = petroleum extract G. lucidum; Ped = petroleum extract D. Confragosa; - = Absent. 
 
Table 2. Antimicrobial activities or potentials of mushroom extracts D. confragosa and G. lucidum. 
Zones of inhibition (mm) 
Organisms 
Antibiotics Mushroom extracts 
 Amoxil Ampicillin Ampiclox Aeg Eeg Peg Aed Eed Ped 
P. aeruginosa 11.0 ± 0.02a - - 11.0 ± 0.02a 12.0 ± 0.01a 12.0 ± 0.01a - - - 
S. aureus 14.0 ± 0.01c 11.0 ± 0.02b 9.0 ± 0.03a 10.0 ± 0.02a,b 11.0 ± 0.02b 11.0 ± 0.03b 12.0 ± 0.01b,a - 19.0 ± 0.02d
P. mirabilis - 14.0 ± 0.03a - - - - - - - 
E. coli 8.0 ± 0.01a 11.0 ± 0.02b 11.0 ± 0.02b 13.0 ± 0.03c 16.0 ± 0.01d 12.0 ± 0.02b,c 12.0 ± 0.03b,c - 13.0 ± 0.01c
K. pneumoniae - 18.0 ± 0.01f 9.0 ± 0.02a 14.0 ± 0.0c - - - - - 
Values are means of triplicates ± SD, Samples carrying the same superscripts in the same row are not significantly different at (P ≤ 0.05); Key: Aeg = aqueous 
extract of G. lucidum; Aed = aqueous extract of D. confragosa; Eeg = ethanolic extract of G. lucidum; Eed = ethanolic extract of D. confragosa; Peg = petro-
leum extract of G. lucidum; Ped = petroleum extract of D. confragosa. 
 
aureus, E. coli and K. pneumoniae with inhibition zones 
of 9.0 ± 0.03 mm, 11.0 ± 0.02 mm and 9.0 ± 0.02 mm 
respectively as shown in Table 2. 
4. Discussion 
The result obtained in this study revealed that the aque- 
ous extract of G. lucidum contain tannins which has an 
anti-inflammatory potential that helps to control gastritis, 
esophagitis and enteritis [5]. It can also heal burns, stops 
bleeding, prevents kidney damage and also of great im- 
portance in the curing of sore throats, diarrhea and dys- 
entery in human, while the ethanolic extract of G. lu- 
cidum contains saponins, tannins and flavonoids. Sapon- 
ins, tannins eand phenolics were present in petroleum 
ether extract of G. lucidum. However, this presence of 
saponin in particular indicates it potential to be used as 
protective against coronary heart disease, stroke and can- 
cer [5], while flavonoids are active against nausea and 
gastro-enteric infections [13]. The aqueous and petroleum 
ether extract of D. confragosa contains tannins and phe- 
nolics, respectively except for the ethanolic extract of D. 
confragosa which has no phytochemical group. 
The inhibitory potentials of the mushroom extracts 
could be attributed to the presence of phytochemicals also 
known as bioactive agents [14] because without these bio- 
active agents, the clinical organisms tend to show resis- 
tant. The ethanolic extract of G. lucidum shows the high- 
est antibacterial potential with an inhibition zone of 16 
mm while the petroleum ether extract of D. confragosa 
equally shows a high zone of inhibition of 19.0 mm. In 
comparison, the aqeous extracts of Ganoderma lucidum 
showed a greater antibacterial potential with their inhibit- 
tion zones greater than that of the commercial antibiotics 
assay for except for ampicillin which had greater inhibit- 
tory potentials. This however is in agreement with the 
report of [15] that Ganoderma lucidum had great anti- 
bacterial potential. Also, the aqueous, ethanol and petro- 
leum ether extract of G. lucidum had a broad spectrum of 
antimicrobial activities due to the presence of more phy- 
tochemical groups compared to the aqeous and petroleum 
ether extracts of D. confragosa. This therefore confirms 
the report of [13] that the extracts of G. lucidum is more 
of medicinal importance in the treatment of diarrhea, kid- 
ney infection, sore throat enteric infections and so on. In 
conclusion, results obtained from this study show that 
some of the solvents (aqueous, ethanol and petroleum 
ether) used for the extraction had a broad spectrum of 
activity which makes it very effective against infection 
causing organisms except for the ethanolic extract of D. 
confragosa. However, if the active ingredients of these 
extracts are characterized and purified through further 
research, it is possible that crystallized therapeutic anti- 
biotics could be produced from them. Further research 
could also be carried out on these mushrooms’ extracts 
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(G. lucidum and D. confragosa) in order to ascertain their 
selective toxicity. 
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